1 in 90 children develop KD by age 5 years, 2 is highly suggestive of a ubiquitous infectious agent affecting young susceptible children who are genetically predisposed. Key features of KD are presented in Box 1. It is important to understand the major pathologic features of KD arteriopathy, briefly summarized in Box 1, because these features predict the adverse clinical outcomes observed in KD patients who develop coronary artery abnormalities. 3 Moreover, knowledge of the many organs and tissues involved in the systemic inflammation of KD assists in understanding the many possible clinical manifestations of the illness (Box 2). 4 Risk factors for KD and the development of coronary artery abnormalities are summarized in Box 3.
INCIDENCE AND MORTALITY RATES
The incidence of KD varies in different countries throughout the world ( Table 1 ) and remains unknown in many regions, especially in those that continue to have a high prevalence of measles, which shares many clinical features with KD. In Japan, there is high recognition and early treatment of the condition, and mortality rates have fallen from 1.4% in 1970 to 0.01% in recent years; fatality rates began to decrease markedly after the introduction of intravenous gammaglobulin therapy in the late 1980s. 8 In the United States, fatality rates are also very low; fatal cases are often associated with delayed or missed diagnoses. 3 Peak months of KD incidence vary somewhat by country, but a consistent theme seems to be a peak during the winter in nontemperate climates. 9 
PATIENT HISTORY
The history is particularly important in KD, as some clinical features of the illness may begin and abate before the patient's presentation. It is recommended that the parent or guardian is asked nonleading questions about symptoms to avoid introducing recall bias. Box 4 lists common features in the history of children with KD. Excessive irritability, refusal to bear weight, redness and swelling of the hands and feet, and an
Box 1 Key features of Kawasaki disease (KD)
An acute onset of prolonged febrile illness in previously healthy children.
The leading cause of acquired heart disease in children in developed nations.
A systemic inflammatory illness affecting many organs and tissues, but leading to long-term consequences almost exclusively confined to medium-sized muscular arteries, particularly the coronary arteries.
KD arteriopathy is characterized by 3 linked pathologic processes: necrotizing arteritis, subacute/chronic arteritis, and luminal myofibroblastic proliferation. Necrotizing arteritis occurs in the first 2 weeks after onset and can result in necrosis of the coronary arteries; if the necrosis is extensive, giant coronary artery aneurysms can form, which are associated with severe outcomes. Subacute/chronic arteritis begins in the first 2 weeks and can continue for months to years after onset. It is closely associated with luminal myofibroblastic proliferation, an active proliferative process of smooth muscle cell-derived myofibroblasts and their matrix products, which can lead to progressive arterial stenosis.
The etiology remains unknown, but clinical and epidemiologic features support an infectious cause.
Genetic factors play a role in susceptibility, with Asian children at highest risk. However, children of all racial and ethnic groups can develop KD.
Rowley erythematous, peeling groin rash may be helpful in establishing the diagnosis, as these are not common features of most other diseases in the differential diagnosis. In a child who has received Bacillus Calmette-Gué rin vaccine, redness at the site should prompt consideration of KD 21 ; the mechanism of this response is unknown. Factors associated with higher risk of coronary artery abnormalities in children with KD 7
PHYSICAL EXAMINATION
Age less than or equal to 12 months or greater than or equal to 8 years
Male gender
Longer interval from disease onset to treatment with intravenous gammaglobulin
Failure to respond to initial intravenous gammaglobulin therapy Laboratory features (albumin <3.0 mg/dL, anemia for age, elevated alanine aminotransferase, hyponatremia, thrombocytopenia) a Based on yearly incidence per 100,000 children younger than 5 years in each country. Bulbar conjunctival injection, generally without exudate and often with limbal sparing (see Fig. 1 )
Oral changes: redness of the throat, strawberry tongue, redness of the lips, sometimes with bleeding or peeling of the lips (see Fig. 1 )
Rash: erythematous maculopapular (see Fig. 2) , scarlatiniform, or erythema multiforme, sometimes with marked groin erythema and desquamation Extremity changes: redness and swelling of the hands and feet during the first week; typical periungual desquamation occurs in the second or third week (Fig. 3) Cervical lymphadenopathy 1.5 cm or more in diameter
Illness not explained by other known disease process Fig. 1 . Conjunctival injection and red lips in a child with acute Kawasaki disease (KD).
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OTHER CLINICAL MANIFESTATIONS OF KAWASAKI DISEASE
Children with KD can present with shock syndrome; such patients are at higher risk of intravenous gammaglobulin (IVIG) resistance and of developing coronary artery abnormalities. [22] [23] [24] [25] [26] Although cervical lymphadenopathy is the least commonly observed clinical feature among the classic diagnostic criteria for KD, it can be the dominant clinical feature, and some of these patients also have retropharyngeal phlegmon (without abscess) documented by neck imaging studies.
27-29 KD should be considered in the differential diagnosis of any infant with prolonged fever and aseptic meningitis. 30 
IMAGING AND ADDITIONAL TESTING
Laboratory findings in KD are nondiagnostic, but can support the diagnosis (Box 6). In particular, a child with a low or normal peripheral white blood cell count with a lymphocyte predominance does not have a compatible laboratory profile of KD. In nontemperate climates KD is most prevalent in the winter, when many respiratory viruses are circulating. Therefore, some children with KD will concurrently have infection with one of these viruses; this should not preclude the diagnosis in cases with clinical and laboratory features of KD. Echocardiography can be very useful in assessing a child for possible KD, as a right or left anterior descending coronary artery z score greater than 2.5 is highly supportive of the diagnosis, 31, 32 and 30% of KD patients have abnormal coronary artery z scores at the time of initial diagnosis, in the first 10 days of illness. 33, 34 The presence of 3 of the following echocardiographic findings should also increase clinical suspicion of KD: pericardial effusion, lack of tapering of the coronary arteries, a coronary artery z score of 2 to 2.5 of the right or left anterior descending coronary arteries, decreased left ventricular function, and mitral regurgitation. 
Box 6 Laboratory findings
Normal peripheral white blood cell count with left shift, or elevated white blood cell count with predominance of neutrophils 
DIAGNOSIS OF INCOMPLETE (ATYPICAL) KAWASAKI DISEASE
Although the classic diagnostic criteria are the mainstay of diagnosis, some children with KD, particularly infants, manifest fever with fewer than 4 of the 5 clinical signs described in Box 5; these children are considered to have incomplete KD. In some infants, the clinical findings are mild, and may not be noted unless there is a high index of suspicion for KD. Unfortunately, coronary artery abnormalities in incomplete cases can be as severe as in classic cases. Because incomplete KD can be difficult to diagnose and has potentially severe consequences that may be prevented by early treatment, the American Heart Association Committee on Endocarditis, Rheumatic Fever, and Kawasaki Disease developed a treatment algorithm combining laboratory and echocardiographic findings with clinical signs and symptoms to identify patients who may benefit from therapy for incomplete KD (Fig. 4) . 7 
PRIMARY THERAPY
All patients diagnosed with KD should be treated with 2 g/kg IVIG with oral high-dose aspirin (80-100 mg/kg/d divided every 6 hours) as soon as possible after diagnosis. 35 IVIG significantly reduces the prevalence of coronary artery abnormalities when given within the first 10 days of illness, 35, 36 and improves myocardial function. 37 However, improved echocardiographic imaging and use of body surface area-adjusted z scores to identify coronary artery dilation has led to the realization that coronary artery injury likely occurs in many patients in the first week of illness, 33, 34 and that coronary artery z scores greater than 2 can be observed in 18% of KD children at about 6 weeks after onset even with treatment within the first 10 days. 34 This finding emphasizes the need for early diagnosis and treatment. At least 80% of KD patients respond to initial therapy with IVIG and aspirin with resolution of fever, improvement in clinical signs and symptoms, and decreased laboratory markers of inflammation. Aspirin is maintained at high doses for anti-inflammatory effect until the patient is afebrile for 2 to 3 days; at some centers, it is continued until the 14th day of illness. Aspirin is then reduced to antiplatelet doses of 3 to 5 mg/kg/d in a single daily dose, and continued until echocardiography at 6 to 8 weeks after the onset remains normal and acute-phase reactants have normalized. In patients who develop coronary artery abnormalities, low-dose aspirin is continued indefinitely. In patients with severe coronary artery abnormalities, clopidogrel and/or anticoagulation therapy with warfarin or low molecular weight heparin may be indicated, and consultation with a pediatric cardiologist is advised. 7 
RESEARCH STUDIES ON ADJUNCTIVE PRIMARY THERAPY
Unfortunately, approximately 15% to 20% of children with KD do not respond to initial IVIG therapy, with persistence of fever 36 hours after completion of IVIG infusion, and these patients are at increased risk of developing coronary artery abnormalities. Some KD patients, especially infants, can develop coronary artery abnormalities despite apparent clinical response to IVIG treatment given in the first 10 days of illness. Therefore, recent research has focused on the study of combination immunomodulatory therapies given with IVIG as primary therapy for KD. A randomized study of a single 30 mg/kg dose of methylprednisolone administered with IVIG did not reveal a significant improvement in outcomes. 38 A randomized, double-blind, placebo-controlled trial of infliximab (a tumor necrosis factor a inhibitor) for intensification of primary therapy for KD did not show a reduction in treatment resistance nor a reduction in the overall prevalence of coronary artery abnormalities when infliximab was administered with IVIG, although the addition of infliximab did result in lower levels of C-reactive protein and absolute neutrophil counts 24 hours after the infusion. 39 More promising was the Randomized controlled trial to Assess Immunoglobulin plus Steroid Efficacy for Kawasaki disease (RAISE study), which demonstrated improvement in coronary artery outcomes in Japanese patients with high-risk KD when prednisolone was given with IVIG and continued for 15 days after normalization of the C-reactive protein level. 40 A randomized trial of cyclosporin with IVIG for Japanese children with high-risk KD is presently under way in Japan, and the results of this study will also be of interest. Because the identification of risk scoring systems with high sensitivity for the prediction of coronary artery abnormalities in mixed ethnic populations has proved elusive, application of the RAISE study protocol or other high-risk protocols to KD children in countries such as the United States and Canada is not presently feasible. 41 
REFRACTORY KAWASAKI DISEASE
Refractory KD generally refers to the persistence of fever for 36 hours or longer after completion of initial IVIG infusion. Patients with IVIG resistance have a higher prevalence of coronary artery abnormalities. 42 Most of these patients respond to a second 2 g/kg dose of IVIG. For those patients who do not respond to a second dose of IVIG, several options for treatment exist, although controlled data are lacking (Box 7).
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CLINICAL OUTCOMES AND COMPLICATIONS
Most children with KD respond to IVIG, and those who do not develop coronary artery abnormalities by 4 to 6 weeks after the onset of fever have no known adverse outcomes. In patients who develop coronary artery dilation or aneurysm formation, outcomes depend on the severity of coronary artery disease. In severe cases giant coronary artery aneurysms can form, which can rarely rupture, and virtually always thrombose to a varying extent. Patients with this severe complication of KD are generally maintained on antiplatelet and anticoagulation therapy, and are at the highest risk for thrombotic occlusion and myocardial infarction, in some cases requiring catheter interventions or coronary artery bypass surgery. However, coronary artery stenosis in KD patients can also be caused by luminal myofibroblastic proliferation (LMP) with or without thromboses. LMP is an active proliferative process of smooth muscle cellderived myofibroblasts and their matrix products that can result in progressive arterial stenosis. 3 In rare cases, LMP or thrombosis can result in such significant stenoses of multiple coronary arteries that heart transplantation is required. 3, 49 KD can affect all medium-sized muscular arteries outside of the central nervous system, but peripheral arterial aneurysms seem to occur only in children with severe coronary artery disease. The most commonly affected arteries are the axillary, brachial, and inguinal arteries; aneurysms in these arteries rarely result in morbidity or mortality. 
